DEF 14A: Renalytix Seeks Shareholder Approval for Key Resolutions at Upcoming General Meeting

Renalytix plc is convening a general meeting on April 22, 2024, to seek shareholder approval for resolutions related to share allotment and disapplication of pre-emption rights to bolster the company's financial position and strategic flexibility.

Summary

• Renalytix plc is holding a General Meeting on April 22, 2024, to vote on four resolutions.
• Resolutions 1 and 2 are ordinary resolutions, requiring a simple majority for approval, while Resolutions 3 and 4 are special resolutions, needing a 75% majority.
• Resolution 1 seeks authorization for the allotment of 26,815,841 ordinary shares (Second Tranche Placing Shares).
• Resolution 2 aims to authorize the allotment of shares up to a nominal amount of 128,391 (approximately 35% of the enlarged issued share capital) and further equity securities up to a nominal amount of 122,277 (approximately one-third of the enlarged issued share capital) for a pre-emptive offer.
• Resolution 3 focuses on disapplying pre-emption rights for the Second Tranche Placing Shares.
• Resolution 4 seeks the disapplication of pre-emption rights for equity securities allotted for cash or treasury shares, up to a nominal amount of 128,391 (approximately 35% of the enlarged issued share capital).
• The Board of Directors unanimously recommends voting in favor of all resolutions.

Sentiment

Score: 7

Explanation: The document is factual and focused on corporate governance matters. The tone is positive regarding the company's ability to secure funding and execute its plans, but there are inherent risks associated with shareholder approval and market conditions.

Positives

• Approval of the resolutions would provide Renalytix with greater financial flexibility to fund its operations and growth plans.
• The resolutions enable the company to respond effectively to market conditions and address business needs.
• The Board believes the resolutions are in the best interest of shareholders and will promote the success of the company.
• The resolutions allow the company to settle amortization and/or interest payments on outstanding convertible bonds in ADSs and/or Ordinary Shares.

Negatives

• If Resolution 1 and 3 are not passed, the placing of the Second Tranche Placing Shares will not complete and the Board considers that it would be significantly constrained in its ability to fund the development of the Company's business.
• If Resolutions 2 and 4 are not approved, the Company would not be able to allot further shares, or grant rights to subscribe or convert any security into shares, in the Company for cash on a non-pre-emptive basis in excess of 11,614,525 Ordinary Shares (other than pursuant to an employees share scheme).

Risks

• Failure to secure shareholder approval for the resolutions could limit the company's ability to raise capital and execute its strategic plans.
• The company's cash runway is dependent on the approval and completion of the Second Tranche Placing Shares.
• The company may face competitive disadvantages if it cannot issue shares as flexibly as its US-incorporated peers.

Future Outlook

Assuming Resolutions 1 and 3 are passed, the net proceeds of the Placing are expected to extend the cash runway of the Company into the fourth quarter of calendar 2024, being used for general working capital requirements.

Management Comments

• The Board of Directors believes that each Resolution is in the best interest of shareholders and most likely to promote the success of the Company for the benefit of its shareholders as a whole.
• Accordingly, the Board of Directors unanimously recommends that you vote in favor of each of the Resolutions.

Industry Context

The resolutions are intended to provide Renalytix with the financial flexibility to compete effectively with its peers, particularly those incorporated in the United States who may not be subject to the same restrictions on issuing shares.

Comparison to Industry Standards

• Many peer companies incorporated in the United States are not subject to the same restrictions on their ability to issue shares as apply to the Company under the Companies Act.
• Approval of Resolutions 2 and 4 by Shareholders will not exempt the Company from any Nasdaq corporate governance or other requirements, including those limiting the issuance of shares.

Related Party Transactions

• Christopher Mills and/or certain investment vehicles connected with him have subscribed for certain Second Tranche Placing Shares.
• Icahn School of Medicine at Mount Sinai has also subscribed for certain Second Tranche Placing Shares.

Stakeholder Impact

• Shareholders: Approval of the resolutions could impact the value of their shares and the company's ability to execute its strategy.
• Employees: The company's ability to fund its operations and growth plans could impact job security and opportunities.
• Customers: The company's ability to develop and commercialize its products could impact the availability of its diagnostic solutions.

Next Steps

• Shareholders to vote on the resolutions by the specified deadlines.
• Company to announce the results of the General Meeting via Form 8-K and RNS announcement.
• If approved, the company will proceed with the allotment of the Second Tranche Placing Shares.

Key Dates

Keywords

share allotment, pre-emption rights, general meeting, shareholder approval, equity securities, ordinary shares, ADS, Renalytix